Evidence map›Paper›PMID 35740460›Full record

ReviewBiomedicines2022

Clinical Application for Tissue Engineering Focused on Materials.

Takahiro Kitsuka, Rikako Hama, Anudari Ulziibayar, Yuichi Matsuzaki, John Kelly, Toshiharu Shinoka

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Advances in Cardiac Tissue Engineering.Bioengineering (Basel, Switzerland) · 2022
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Takahiro KitsukaCenter for Regenerative Medicine, Nationwide Children's Hospital, Columbus, OH 43205, USA.
Rikako HamaCenter for Regenerative Medicine, Nationwide Children's Hospital, Columbus, OH 43205, USA.
Anudari UlziibayarCenter for Regenerative Medicine, Nationwide Children's Hospital, Columbus, OH 43205, USA.ORCID 0000-0002-5064-0634
Yuichi MatsuzakiCenter for Regenerative Medicine, Nationwide Children's Hospital, Columbus, OH 43205, USA.
John KellyCenter for Regenerative Medicine, Nationwide Children's Hospital, Columbus, OH 43205, USA.
Toshiharu ShinokaCenter for Regenerative Medicine, Nationwide Children's Hospital, Columbus, OH 43205, USA.ORCID 0000-0002-5173-9249
Nationwide Children's Hospital · US

Funding

Gunze (Japan) Gunze
6 · The paper itself

Abstract

Cardiovascular-related medical conditions remain a significant cause of death worldwide despite the advent of tissue engineering research more than half a century ago. Although autologous tissue is still the preferred treatment, donor tissue is limited, and there remains a need for tissue-engineered vascular grafts (TEVGs). The production of extensive vascular tissue (>1 cm3) in vitro meets the clinical needs of tissue grafts and biological research applications. The use of TEVGs in human patients remains limited due to issues related to thrombogenesis and stenosis. In addition to the advancement of simple manufacturing methods, the shift of attention to the combination of synthetic polymers and bio-derived materials and cell sources has enabled synergistic combinations of vascular tissue development. This review details the selection of biomaterials, cell sources and relevant clinical trials related to large diameter vascular grafts. Finally, we will discuss the remaining challenges in the tissue engineering field resulting from complex requirements by covering both basic and clinical research from the perspective of material design.

Indexed as

3D printingbiodegradable scaffoldsclinical trialsdecellularized tissueelectrospinningsilk fibroinsynthetic polymerstissue-engineered vascular grafts (TEVGs)tissue engineering

Identifiers

PMID35740460
PMCPMC9220152
OpenAlexW4283012111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.